We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+30.69%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.46B
AUM Growth
+$453M
Cap. Flow
-$312M
Cap. Flow %
-5.72%
Top 10 Hldgs %
38.94%
Holding
132
New
22
Increased
22
Reduced
29
Closed
18

Top Buys

Rank Stock Value
1
AVBP icon
ArriVent BioPharma
AVBP
+$61.1M
2
CYTK icon
Cytokinetics
CYTK
+$52.8M
3
ESPR
Esperion Therapeutics
ESPR
+$33.3M
4
MRK icon
Merck
MRK
+$32.2M
5
QTTB icon
Q32 Bio
QTTB
+$31M

Top Sells

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$147M
2
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$93.5M
3
UTHR icon
United Therapeutics
UTHR
+$84.9M
4
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$71.7M
5
SWTX
SpringWorks Therapeutics
SWTX
+$69.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.1%
2 Miscellaneous 0.9%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCM
126
DELISTED
R1 RCM Inc. Common Stock
RCM
– –
-4,803,200
Closed -$50.8M
FUSN
127
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
– –
-3,122,770
Closed -$30M
AMAM
128
DELISTED
Ambrx Biopharma Inc
AMAM
– –
-296,000
Closed -$4.22M
RYZB
129
DELISTED
RayzeBio, Inc. Common Stock
RYZB
– –
-2,365,213
Closed -$147M
GRCL
130
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
– –
-9,308,726
Closed -$93.5M
THRX
131
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
– –
-17,713,600
Closed -$71.7M
2 3 4 5
6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q1 2024 Portfolio in Review

As of Q1 2024, OrbiMed held 132 positions worth $5.46B, up 9% from $5.01B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

OrbiMed withdrew a net $312M in Q1 2024, closing 18 positions and reducing 29 holdings. Its most notable exit was RayzeBio, Inc. Common Stock, an estimated $147M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous and Industrials.

Against the trend, OrbiMed opened a new position in ArriVent BioPharma worth $54.1M.

  • OrbiMed's largest Q1 2024 buy was ArriVent BioPharma: 3,027,328 shares worth $54.1M.
  • OrbiMed added most to Merck in Q1 2024, an estimated $32.2M increase.
  • OrbiMed's biggest Q1 2024 reduction was SpringWorks Therapeutics, cutting an estimated $69.9M.
  • OrbiMed fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $147M.
  • OrbiMed's ten largest holdings make up 39% of its $5.46B portfolio in Q1 2024.
  • OrbiMed opened 22 new positions and closed 18 in Q1 2024.
  • OrbiMed's portfolio value rose 9% quarter-over-quarter to $5.46B.

Based on OrbiMed's 13F filing for Q1 2024, filed 15 May 2024.